| Ytd | -95.26% | |
| 1y | -91.91% |
| Open | 30.50 | Prev Close | 29.36 | Low | 29.84 | High | 37.00 | Mkt Cap | 32.27M |
| Vol | 138.74K | Avg Vol | 30.78K | EPS | -214.01 | P/E | N/A | Forward P/E | -5.68 |
| Beta | 0.71 | Short Ratio | 2.27 | Inst. Own | 25.53% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 30.70 | 200-d Avg | 88.35 | 1yr Est | 9.00 |
QNCX News
What happened Quince Therapeutics, Inc. (NASDAQ: QNCX) said it changed its name to IRulya Therapeuti
Company common stock to trade on Nasdaq under the symbol “IRLA” effective October 12, 2026 Key Manag
Raymond James analyst Tiago Fauth initiates coverage on Quince Therapeutics (NASDAQ:QNCX) with a
Quince Therapeutics (NASDAQ: QNCX) stockholders approved five proposals at the company's Oct. 6, 202
Quince Therapeutics, Inc. (QNCX) Shareholder/Analyst Call Prepared Remarks Transcript
Quince Therapeutics, Inc. (QNCX) Discusses LAM-001 Clinical Progress in Pulmonary Hypertension and B
Analysts initiated coverage: ARES Overweight, $150; MGEE Neutral, $76; TTRX Buy, $24; QNCX Buy, $70;
Rodman & Renshaw analyst Seema Sheoran initiates coverage on Quince Therapeutics (NASDAQ:QNCX
Citizens analyst Jonathan Wolleben upgrades Quince Therapeutics (NASDAQ:QNCX) from Market Perform
Gainers Decoy Therapeutics (NASDAQ:DCOY) shares rose 84.0% to $4.71 during Tuesday's pre-market
SOUTH SAN FRANCISCO, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: Q
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: Q
Cantor Fitzgerald analyst Olivia Brayer Saunders reiterates Quince Therapeutics (NASDAQ:QNCX) wit
Quince Therapeutics (NASDAQ:QNCX) reported quarterly losses of $(12.31) per share which beat the ana
Completed acquisition of Orphai Therapeutics, adding LAM-001, an inhaled formulation of rapamycin fo
Oppenheimer analyst Mazahir Alimohamed initiates coverage on Quince Therapeutics (NASDAQ:QNCX) wi
SOUTH SAN FRANCISCO, Calif. , June 30, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: Q
Leerink Partners analyst Joseph Schwartz initiates coverage on Quince Therapeutics (NASDAQ:QNCX)
Cantor Fitzgerald analyst Olivia Brayer Saunders initiates coverage on Quince Therapeutics (NASDA
Quince Therapeutics, Inc. (QNCX) Shareholder/Analyst Call Prepared Remarks Transcript
Quince Therapeutics, Inc. (QNCX) M&A Call Prepared Remarks Transcript
SOUTH SAN FRANCISCO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: QNC
The acquisition is structured as a stock-for-stock merger, pursuant to which all outstanding equity
Data from Phase 2a study of LAM-001 on top of standard of care in PH-ILD patients with refractory PH
SOUTH SAN FRANCISCO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: QNC
SOUTH SAN FRANCISCO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: QNC
US stocks rose, Dow up 2.85%, Nasdaq up 3.33%, S&P 500 up 2.54%. Consumer discretionary shares u
Levi Strauss (LEVI) reported strong Q1 2026 results, raising revenue & earnings guidance. Other
Quince Therapeutics, Inc. (Nasdaq: QNCX) today announced the successful settlement of the company
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq:
Shares of Quince Therapeutics, Inc. (NASDAQ: QNCX - Get Free Report) have earned a consensus recomme
Shares of Quince Therapeutics, Inc. (NASDAQ: QNCX - Get Free Report) have received an average rating